US · Healthcare · Medical Devices
EPS came in at -0.35 against a street estimate of -0.27 — a miss of 29.6%.
Analysts rate Establishment Labs Holdings Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $98.50.
CONFIDENT Establishment Labs delivered strong Q3 growth, first positive free cash flow, and raised 2026 revenue guidance. U.S. utilization, minimally invasive products, and reconstruction create upside, while distributor mix pressures margins. Q3 FY26 U.S. revenue was $26 million and OUS revenue was $46 million. Distributor markets represented approximately 60% of OUS revenue, above the planned 50%, supporting dollars but reducing margin percentage. Analysts focused on international demand, utilization, margins, implant sizing, and reconstruction readiness. Management emphasized seasonality, targeted commercial investment, distributor mix, and ongoing regulatory progress. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| JW Asset Management, LLC | 9.04% |
| RTW INVESTMENTS, LLC | 8.91% |
| BlackRock Inc | 5.31% |
| T. Rowe Price Associates, Inc. | 5.15% |
| Brown Advisory Holdings Inc | 4.41% |
| Findell Capital Management LLC | 3.68% |
| Mudita Advisors LLP | 2.43% |
| William Blair Investment Management, LLC | 2.40% |
| Document | Date |
|---|---|
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue rose 33.9% year over year to $72.0 million, from $53.8 million. • U.S. revenue increased 119.0% to $26.0 million; | 2026-10-29 |
| Material agreement · Q4 2026 BUSINESS & SEGMENT HIGHLIGHTS • On October 14, 2026, Establishment Labs Holdings Inc., through wholly owned subsidiary Establishment Labs, S.A. (ELSA | 2026-10-15 |
| Quarterly report · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Revenue (6 months 2026): $127.4 million vs. | 2026-08-07 |
| Results announced · Q3 2026 ESTABLISHMENT LABS HOLDINGS INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $67.5 million, up 31.7% year-over-year from $51.3 m | 2026-08-06 |
| Board / officer change · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. – FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Company is Establishment Labs Holdings Inc., a medical device/he | 2026-06-29 |
| Shareholder vote results · Q2 2026 ESTABLISHMENT LABS HOLDINGS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Shareholders held May 22, 2026 • Company ticker: ESTA (Nasd | 2026-05-22 |
| Quarterly report · Q1 2026 ESTABLISHMENT LABS HOLDINGS INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q1 2026: $59.9 million (up 44.7% vs. Q1 2025: $41.4 million) • Ne | 2026-05-08 |
| Results announced · Q2 2026 ESTABLISHMENT LABS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue Q1 2026: $59.9 million, up 44.7% year-over-year from $41.4 million in | 2026-05-06 |
Readable in the app.
| Announcement | Date |
|---|---|
| Master supply agreement extended through 2031 for medical-grade silicone products Establishment Labs extended its supply agreement with NuSil Technology, a supplier of medical-grade silicone used in certain of its products. The amendment is effective January 1, 2027, and | 2026-10-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Establishment Labs Holdings Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.